Compare Pfizer Inc (PFE) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs J M Smucker Co — how do they compare? Pfizer Inc trades at $28.1 (market cap $158.56B), while J M Smucker Co trades at $118.5 (market cap $12.76B). The key difference: Pfizer Inc is far larger — about 12.4× J M Smucker Co's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and J M Smucker Co for 74 Days on average.
| PFE | SJM | |
|---|---|---|
Market Cap | $158.56B | $12.76B |
Volume | 44,138,282 | 1,300,545 |
Sector | Health | Consumer Staples |
52-Week High | $29.02 | $132.34 |
52-Week Low | $23.67 | $89.53 |
Typical Hold Time | 158 Days | 74 Days |
Enterprise Value | $210.06B | $19.61B |
Dividend Yield | 6.18% | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
SJM trades at $115.93, down 0.74% on the day, with a bearish technical signal and recent earnings beats. The company reported a net loss of $1.23 billion in 2025 despite revenue growth to $8.73 billion, though 2026 forecasts show a return to profitability. Analyst consensus is bullish with a $138.23 price target, and a $1.12 dividend is scheduled for September 2026.
The stock presents a mixed outlook: strong analyst support and dividend yield offer upside, but high P/E of 55.8 and recent net losses pose valuation and execution risks. Key catalysts include sustained earnings growth and margin improvement, while competitive pressures and debt levels remain concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
